Literature DB >> 20345933

Alterations of intracerebral γ-aminobutyric acid (GABA) levels by titration with levetiracetam in patients with focal epilepsies.

M Thorsten Doelken1, Marc T Doelken, Thilo Hammen, Wolfgang Bogner, Angelika Mennecke, Andreas Stadlbauer, Uwe Boettcher, Arnd Doerfler, Hermann Stefan.   

Abstract

PURPOSE: The objective of this study was to determine if levetiracetam (LEV) modulates brain γ-aminobutyric acid (GABA) in patients with epilepsy.
METHODS: Occipital GABA was assessed by protein magnetic resonance spectroscopy (¹H-MRS) in 16 patients with focal epilepsy at baseline and following the initiation of oral administration of LEV as monotherapy. Responder profiles were calculated as percentage of baseline seizure frequency. Alterations of GABA/Cr (creatine) of baseline measurements compared to GABA/Cr under LEV therapy were analyzed by Student's t-test for paired samples.
RESULTS: After administration of LEV, partial seizure reduction (> 50%) was noticed in 5 of 16 patients (31%; 7 of 16 (44%) patients turned out to be free of seizures. Patients with 50-100% seizure reduction under LEV titration were referred to as LEV responders. Of the 32 GABA spectra, only 22 (approximately 70%) yielded a result that met the criteria for spectral quality; therefore, GABA/Cr data from only seven patients were paired. A significant increase of GABA/Cr during titration with LEV was noted in patients responding to LEV (n = 5; p = 0.007). No differences in baseline GABA/Cr levels were detected between patients with and without previous antiepileptic treatment (p = 0.74). DISCUSSION: The increasing GABA/Cr levels under drug titration only in LEV-responding epilepsy patients suggest a more complex and indirect influence of LEV on the GABAergic system. Wiley Periodicals, Inc.
© 2010 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20345933     DOI: 10.1111/j.1528-1167.2010.02544.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  9 in total

Review 1.  GABA-based evaluation of neurologic conditions: MR spectroscopy.

Authors:  L M Levy; A J Degnan
Journal:  AJNR Am J Neuroradiol       Date:  2012-01-19       Impact factor: 3.825

Review 2.  In vivo magnetic resonance spectroscopy of GABA: a methodological review.

Authors:  Nicolaas A J Puts; Richard A E Edden
Journal:  Prog Nucl Magn Reson Spectrosc       Date:  2011-06-12       Impact factor: 9.795

Review 3.  GABAergic contributions to alcohol responsivity during adolescence: insights from preclinical and clinical studies.

Authors:  Marisa M Silveri
Journal:  Pharmacol Ther       Date:  2014-03-11       Impact factor: 12.310

4.  Proton MR spectroscopy-detectable major neurotransmitters of the brain: biology and possible clinical applications.

Authors:  N Agarwal; P F Renshaw
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-29       Impact factor: 3.825

Review 5.  Levetiracetam Mechanisms of Action: From Molecules to Systems.

Authors:  Itzel Jatziri Contreras-García; Noemí Cárdenas-Rodríguez; Antonio Romo-Mancillas; Cindy Bandala; Sergio R Zamudio; Saúl Gómez-Manzo; Beatriz Hernández-Ochoa; Julieta Griselda Mendoza-Torreblanca; Luz Adriana Pichardo-Macías
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-13

6.  Investigation of glutamine and GABA levels in patients with idiopathic generalized epilepsy using MEGAPRESS.

Authors:  Fahmida A Chowdhury; Ruth L O'Gorman; Lina Nashef; Robert D Elwes; Richard A Edden; James B Murdoch; Gareth J Barker; Mark P Richardson
Journal:  J Magn Reson Imaging       Date:  2014-03-03       Impact factor: 4.813

Review 7.  Current human brain applications and challenges of dynamic hyperpolarized carbon-13 labeled pyruvate MR metabolic imaging.

Authors:  Yan Li; Daniel B Vigneron; Duan Xu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-08-25       Impact factor: 9.236

8.  Chronic levetiracetam (Keppra®) treatment increases the reinforcing strength of cocaine in rhesus monkeys.

Authors:  Paul W Czoty; Robert W Gould; Cormac A O'Donovan; Michael A Nader
Journal:  Pharmacol Biochem Behav       Date:  2021-06-08       Impact factor: 3.697

9.  Catatonia in a patient with bipolar disorder type I.

Authors:  Ather Muneer
Journal:  J Neurosci Rural Pract       Date:  2014-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.